Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is the fifth most common cause of cancer death in the UK. Its poor prognosis is attributed to late detection and limited therapeutic options. Expression of SULF2, an endosulfatase that modulates heparan sulfate proteoglycan 6-O-sulfation and is rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhasan, Sari F, Haugk, Beate, Ogle, Laura F, Beale, Gary S, Long, Anna, Burt, Alastair D, Tiniakos, Dina, Televantou, Despina, Coxon, Fareeda, Newell, David R, Charnley, Richard, Reeves, Helen L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5046211/
https://www.ncbi.nlm.nih.gov/pubmed/27560551
http://dx.doi.org/10.1038/bjc.2016.264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5046211/
https://www.ncbi.nlm.nih.gov/pubmed/27560551
http://dx.doi.org/10.1038/bjc.2016.264

Ejemplares similares